RxDoctor Payments Data

Christopher Anderson, MD

Sports Medicine · Spokane Valley, WANPI 1205887056

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,603 of the $2,580 with a category attached, or 62.1%. 7 manufacturers reported payments, led by Arthrex at 43.4% of the total. Reporting peaked in 2023 at $2,035 and has fallen 91.5% since, to $172 in 2025.

$2,580in general payments, 2019–2025

Across 37 payments — averaging $69.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arthrex$1K
  • Summit Surgical Corp.$945
  • Johnson & Johnson$250
  • Sawtooth Surgical Solutions Inc$105
  • Vericel Corporation$100
  • Stryker$38
  • plus $23 from 1 others

What the payments were for

  • Travel & lodging$1,60362%
  • Food & beverage$95637%
  • Education$211%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Arthrex18$1,120
Summit Surgical Corp.7$945
Johnson & Johnson5$250
Sawtooth Surgical Solutions Inc2$105
Vericel Corporation3$100
Stryker1$38
Boston Scientific1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,580 in reported general payments places this provider in the 70th percentile of 132 sports medicine providers in Washington.

See all sports medicine providers in Washington

Medicare billing

Part B allowed, 2024
$95,496
Medicare patients
195
Services billed
2,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban52$20,379
Celecoxib17$789
Cephalexin71$351
Oxycodone Hcl32$248
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen12$92
Ondansetron Hcl21$69
Clindamycin Hcl14$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$250$20,37952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 132 sports medicine providers in Washington.

Other sports medicine in Spokane Valley

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →